Discontinued Operations - Schedule of discontinued operation in operations statement (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Discontinued operation operating expense
Net loss from discontinued operations, net of tax benefit	$ (2,385,506)	$ (2,807,643)
Elusys Therapeutics business unit
Discontinued operation operating expense
Research and development		1,283,982
Selling, general and administrative		693,211
Amortization of intangible assets		727,500
Change in fair value of contingent consideration		109,500
Total operating expenses		2,814,193
Loss from operations		(2,814,193)
Other income		(6,550)
Total non-operating gain		(6,550)
Net loss from discontinued operations before income taxes		(2,807,643)
Net loss from discontinued operations, net of tax benefit		$ (2,807,643)